Nanoplexed Poly I:C BO-112

Developed for: dedifferentiated liposarcoma · fibrosarcoma · leiomyosarcoma · malignant peripheral nerve sheath tumor · myxofibrosarcoma · pleomorphic rhabdomyosarcoma · retroperitoneal sarcoma · spindle cell sarcoma
+3 more
· synovial sarcoma · undifferentiated high grade pleomorphic sarcoma of bone · undifferentiated pleomorphic sarcoma, inflammatory variant
Investigated by: Highlight Therapeutics · Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI)

today NCT04420975 · Ph 1

2021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04420975	Oct 2020 → Jan 2027 expected	dedifferentiated liposarcoma, fibrosarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor +7	Jonsson Comprehensive Cancer Center	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Nanoplexed Poly I:C BO-112	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04420975 ↗
Route	Other	“Given intratumorally” NCT04420975 ↗